India-Netherlands-Sweden collaborative programme on HIV/AIDS research

Image
ANI New Delhi [India]
Last Updated : May 22 2018 | 3:55 PM IST

The Governments of India and The Netherlands on Wednesday will announce the launch of the first-of-its-kind collaborative research programme on HIV/AIDS, between India, The Netherlands and Sweden.

Bruno Bruins, Minister for Medical Care, Government of the Netherlands and Dr Renu Swarup, Secretary, Department of Biotechnology, Government of India, will be jointly announcing it and addressing the stakeholders and media.

The programme is aimed at harnessing complementary research strengths and diverse expertise across the three nations to catalyze the development of better tools to understand and address the burgeoning global epidemic of HIV.

This unique collaboration will enable a multitude of cross-learning opportunities in HIV/AIDS research to address current unmet needs and emerging challenges such as drug resistance, viral diversity, and coinfections and comorbidities.

It will focus on accessing relevant populations of research interest, and leveraging next-generation technologies and advanced predictive analytics to better understand the geographic diversity and different clades of the virus, as well as the divergent human immune responses based on genetic, immunological and behavioural determinants. This information will be key in developing new and improved tools for prevention, treatment and possible cure for HIV in the near future.

The endeavour brings together various Government and non-Government institutions in India including the Department of Biotechnology (DBT), National AIDS Control Organization (NACO) and International AIDS Vaccine Initiative (IAVI), along with Centers of Research Excellence such as Indian Institute of Science (IISc), Institute of Genomics and Integrative Biology (IGIB), Institute of Bioinformatics (IOB), Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), and Y. R. Gaitonde Centre for AIDS Research and Education (YRGCARE) in India; Erasmus Medical Centre in The Netherlands, and Karolinska Institute in Sweden.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 22 2018 | 3:55 PM IST

Next Story